Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Ando

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
International Journal of Hematology|April 8, 2022
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapyChikashi Yoshida, Takeshi Kondo, Tomoki Ito, et al.
British Journal of Haematology|April 25, 2023
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in JapanTomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, et al.
Haematologica|June 6, 2024
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb resultsShinya Rai, Won Seog Kim, Kiyoshi Ando, et al.
Haematologica|October 6, 2022
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb resultsShinya Rai, Won Seog Kim, Kiyoshi Ando, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Cancer Science|January 7, 2023
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemiaSatoshi Wakita, Atsushi Marumo, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
International Journal of Hematology|April 8, 2022
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapyChikashi Yoshida, Takeshi Kondo, Tomoki Ito, et al.
British Journal of Haematology|April 25, 2023
Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in JapanTomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, et al.
Haematologica|June 6, 2024
Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb resultsShinya Rai, Won Seog Kim, Kiyoshi Ando, et al.
Haematologica|October 6, 2022
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb resultsShinya Rai, Won Seog Kim, Kiyoshi Ando, et al.
International Journal of Hematology|April 4, 2022
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemiaAtsushi Marumo, Satoshi Wakita, Kaoru Morita, et al.
Cancer Science|January 7, 2023
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemiaSatoshi Wakita, Atsushi Marumo, Kaoru Morita, et al.
Blood Advances|August 27, 2021
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemiaSatoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, et al.
Pageof 13